Key Highlights: Implications: The Elephas–Neuberg partnership brings a functional, live‑tissue test for immunotherapy response into India’s mainstream diagnostics, giving oncologists an&nb...
Key Highlights: Implications: The launch positions Eisai to capture first-mover advantage in India’s underpenetrated dementia market, where prevalence is already large and expected t...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s eme...
Latest Developments in Cell and Gene Therapy Manufacturing Cell and gene therapies are rapidly emerging as one of the most transformative areas in modern medicine. These advanced therapies aim t...
Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: Vyome is buying its way into a large, fast‑growing immunology market with next‑generation, more selective JAK inhibitors, without overextending its balan...
Key Highlights: Implications: With legal access to the Charpentier CRISPR/Cas9 patents, Aurigene can now run gene‑editing projects (target validation, disease models, f...
Latest Developments in Rare Disease Policy Rare diseases collectively affect millions of patients worldwide, yet each individual condition impacts a relatively small population. Historically, li...
